Product Information
TOPIRAMATE ER 200 MG SPRINK CAP is a generic product labeled by Vitruvias Therapeutics Inc., priced at $9.5420 per EA under NDC 69680018130. Its NADAC has been published 65 times since Jul 9, 2025.
FDA first approved this application on Nov 5, 2024. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
200 mg/1
Manufacturer
Vitruvias Therapeutics Inc.NDC
69680018130
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA215638FDA Approved
11/5/2024
TE Code
AB2
On Market Since
4/7/2025
Pharmacological Classes
Price Statistics
The NADAC for TOPIRAMATE ER 200 MG SPRINK CAP has been published 65 times since Jul 9, 2025, and over the history we have for it it has declined 29.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $9.5420 per EA |
|---|---|
| All-time high | $13.5037 (Jul 16, 2025) |
| All-time low | $9.5420 (Sep 23, 2026) |
| 52-week high | $13.1216 |
| 52-week low | $9.5420 |
| Median price | $11.4675 |
| Average price | $11.8290 |
| Largest weekly change | -8.1% (Aug 19, 2026) |
| Weeks tracked | 65 |
| Tracking since | Jul 9, 2025 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Vitruvias Therapeutics Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPIRAMATE ER 200 MG SPRINK CAP?
The current National Average Drug Acquisition Cost (NADAC) for TOPIRAMATE ER 200 MG SPRINK CAP, manufactured by Vitruvias Therapeutics Inc., is $9.5420 per EA (NDC 69680018130), effective Sep 30, 2026.
How has the price of TOPIRAMATE ER 200 MG SPRINK CAP changed over time?
Over the history we have for it, the NADAC for TOPIRAMATE ER 200 MG SPRINK CAP has declined 29.3%. It has been tracked across 65 weekly CMS publications since Jul 9, 2025.
What are the highest and lowest recorded NADAC prices for TOPIRAMATE ER 200 MG SPRINK CAP?
Since Jul 9, 2025, the NADAC for TOPIRAMATE ER 200 MG SPRINK CAP has ranged from a low of $9.5420 (Sep 23, 2026) to a high of $13.5037 (Jul 16, 2025), with a median of $11.4675 per EA.
Are there cheaper alternatives to TOPIRAMATE ER 200 MG SPRINK CAP?
5 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TOPIRAMATE ER 200 MG SPRINK CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures TOPIRAMATE ER 200 MG SPRINK CAP?
TOPIRAMATE ER 200 MG SPRINK CAP (NDC 69680018130) is labeled by Vitruvias Therapeutics Inc., and CMS classifies it as a generic product.